Eisai Co. Ltd. and Eli Lilly and Co. on April 8 said they still plan to seek accelerated U.S. approval for experimental Alzheimer’s drugs even after the Medicare health plan decided to severely limit coverage of medicines approved in that manner.

Biogen Inc. on July 8 said the U.S. Food and Drug Administration narrowed use of the company’s Alzheimer’s drug after the regulatory agency drew sharp criticism for its broad approval of the drug in June 2021 without proof of clear benefit against the disease.

Seattle-based AltPep Corporation raised $23.15 million in a Series A financing round to take the company’s breakthrough amyloid targeting platform to development.

Biomarkers will be critical to developing precision medicine for Alzheimer’s disease, and phosphorylated tau (P-tau) may enable earlier and more accurate detection, according to Eli Lilly-associated researchers.

Framingham, Massachusetts-based Alzheon was awarded a $47 million grant over five years from the U.S. National Institute on Aging (NIA), part of the National Institutes of Health, to assist with a Phase III clinical trial of ALZ-801.

A specially designed clinical study that was the first disease prevention trial to study Alzheimer’s disease drugs with different mechanisms of action from two different pharmaceutical companies failed to hit the primary endpoint.

Little headway has been made in developing a treatment for Alzheimer’s disease, but that could be changing.

Novartis, Amgen and the Banner Alzheimer’s Institute announced they are halting two pivotal Phase II/III clinical trials in the Alzheimer’s Prevention Initiative Generation Program.

Takeda Pharmaceutical Co. Ltd. will discontinue a late-stage study testing the company’s experimental treatment for amyloidosis, which did not meet the first of two main goals.

Unfortunately, 2018 marked yet another bad year for Alzheimer’s disease drug development, with at least half-a-dozen major clinical drug trial failures.